---
source_image: "chart+legal-filing+affidavit+invoice__EFTA01452939_20260130_p001_i001.png"
source_pdf: "EFTA01452939.pdf" 
method: pdf_text
words: 683
confidence: 1.00
extracted: 2026-02-15T18:38:08.073987
---

Deutsche Bank 
Markets Research 
Rating 
Buy 
North America 
United States 
Health Care 
Health Care Facilities 
and Services 
(kimi)0117 
HCA Holdings, Inc. 
HCA N 
HCA US 
NYS 
Q4 surgery/mix recovering; 2014 / 
ACA outlook conservative 
Reiterate Buy. F ICA's it:sure: demomtrate best in breed 
(14 operating metrics were not given at time of early Jan. +ve pre-anncmt. 
Actual results highlight a recovery in surgical trends, which boosted 
pricing/mix and helped drive solid C14 EBITDA growth (+6.7% YoY) despite 
weaker inpt medical trends and a tough vol comp. HCA provided initial ACA 
guidance, but mgmt may revisit assumptions on key ACA variables mid-year 
given how fluid the roll-out is. For 2014. ACA initially guided -$100M (+1.5%) 
EBITDA benefit underpinned by 7%-9% reduction in uninsured and slight offset 
by pricing/vol impact for exchange mix. Given strong organic growth trends in 
recent Qs, we believe 2014 EBITDA guidance should prove conservative. 
Q4 CC.: tal.oawaytt fret:O1(S uview rn Itcrely of note) 
11) Volume/prbIng metrics: surgery the bigger story. Weak SS inpt admits (-
1.8%) reflect tough comp, lower flu trends and -50 bps from 2-midnight rule. 
Importantly. HCA does not see 2-midnight rule having material financial 
impact. The bigger vol story in O4 (and last 3 Qs) is surgeries; Q4 surg vol 
(+1.4%) and strength in higher-acuity areas (cardio, ortho, neuro) helped drive 
pricing (RPAA) +4.8% YoY. The ratio of inpt surg / inpt admit rose to 30% (from 
-29% avg past 2 yrs) and ratio is 200-300 bps below peak. A sustained 
rebound in surgical mix could be an upside risk to guidance. 
'(2) 2014 guidance assumes 1%-4% EBITDA growth. Underlying assumptions 
(ex. ACA) include 1-2% adj. admit (vol) growth. 2-3% RPAA (pricing) growth 
and flat margins. Given 2H'13 RPAA growth (+4%) and recovery in surg. RPAA 
seems conservative. Guidance assumes adj. vols improve vs. 2013 flat. The 
key headwinds built-into guidance: $120M lower YoY HITECH and $55M 
higher YoY stock comp which impact growth by 300 bps vs. DBe orig est 200 
bps. We believe guidance implies 2%-5% base growth ex headwinds and ACA. 
'(3) ACA commentary: a reasonable starting point. HCA framed ACA impact as 
a L-T positive, but key variables remain very fluid this year including: (I) 
enrollment for exchange and Medicaid; (2) net new lives; (3) networks and plan 
selection of exchange products. HCA assumes 7-9% reduction of uninsured 
(reasonable) but offset somewhat due to leakage and pricing (conservative). 
Updated estimates: modest adjustment:- to reflect HI TECH, slower /AGA ramp 
2014 EBITDA / EPS are $7.056 / $3.92 from $7.1456 / $4.17. We come out 
above guidance (56.606-$6.856 EBITDA / S3.45-$3.75 EPS ) due to underlying 
growth and ACA. Our model now reflects higher S/O, slightly lower HITECH 
benefit, slightly lower ACA ramp but slightly better rate/mix. 
Valuation and risks: PT remains at $58 or 7.5x 2015 EV/EBITDA 
Our target multiple is in-line with group's L-T average of 6.5x-7.5x. Key risks: 
implementation of PPACA, payer mix changes, Medicare/Medicaid cuts. 
no/I -
co
+ 
Year End Dec 31  
2013A 
2014E 
2015E 
N EPS (USD) 
 
 
3.42 
3.92 
4.77 
EWEN TDA  
7.2 
7.1 
6.2 
Adiustod EBITDA 
6.574 
7.048 
7.749 
Sow< Oa ssay 64nk egvnarn COMPOIN sea 
Six IWO, h â€¢ enpoct of FA$Ifl nqurng the nvon.ong Of mock optee4 
4 February 2014 
Results 
Price at 3 Feb 2013105131 
48.46 
Price Tartlet 
58.00 
52-week ranee 
51.41 - 35.21 
Oarreu Letirteli 
Research Analyst 
(+11 212 250-2629 
darren.lehrich@db.com 
Nniwklvietn 
Research Associate 
(+11 212 260.3070 
joshua.kalenclerian@db.corn 
Darla pantie. CFA 
Research Associate 
(+11 212 250-6587 
dana.nentin@clb.com 
IPTieoiptice 
mcam 'app. ;roc 
 
SIP 06)111,EX 0..tbasten 
Performance (%I 
1n1 
3m 
12m 
Absolute 
.0.6 
2.4 
26.8 
S&P 600 INDEX 
awn Cana Sat 
-4.9 
-1.1 
15.1 
Deutsche Bank Securities Inc. 
Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should 
be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should 
consider this report as only a single factor in making their investment decision. DISCLOSURES AND ANALYST 
CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MICA(P) 054/04/2013. 
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) 
DB-SONY-0110272 
CONFIDENTIAL 
SDNY_GM_00256456 
EFTA01452939